Biologic modulations with nanoparticles

• US 20040038303A1
• Filed: 02/28/2003
• Published: 02/26/2004
• Est. Priority Date: 04/08/2002
• Status: Abandoned Application

• Current Assignee: GeneSegues Inc.
• Original Assignee: GeneSegues Inc.
• Inventors: Unger, Gretchen M.
• Application Number:
  US10/378,044
• Publication Number:
  US 20040038303A1
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 48/0041 the non-active part being polymeric
• CPC Class Codes: A61K 49/0065 the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
• CPC Class Codes: A61K 49/0067 quantum dots, fluorescent nanocrystals
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/5094 Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• CPC Class Codes: A61K 9/5138 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth.

Claims

1. A collection of particles comprising a bioactive component, a surfactant molecule having an HLB value of less than about 6.0 units, a biocompatible polymer, and a cell recognition component, wherein the collection of particles has an average diameter of less than about 200 nanometers as measured by atomic force microscopy following drying of the collection of particles, wherein the cell recognition component has a binding affinity for a cell recognition target, with the target being a member of the group consisting of cell adhesion molecules, immunoglobulin superfamily, cell adhesion molecules, integrins, cadherins, selectins, growth factor receptors, collagen receptors, laminin receptors, fibronectin receptors, chondroitin sulfate receptors, dermatan sulfate receptors, heparin sulfate receptors, keratan sulfate receptors, elastin receptors, and vitronectin receptors.

8. The collection of particles of claim 1 wherein the antisense nucleic acid comprises a non-natural backbone.

2. The collection of particles of claim 2 wherein the cell recognition component is a ligand that has a binding affinity for the cell recognition target and the cell recognition target is a member of the group consisting of immunoglobulin superfamily, cell adhesion molecules, integrins, cadherins, and selectins.

4. The collection of particles of claim 2 wherein the cell recognition component is a ligand that has a binding affinity for the cell recognition target and the cell recognition target is a growth factor receptor.

6. The collection of particles of claim 2 wherein the cell recognition component is a ligand that has an affinity for the cell recognition target and the cell recognition target is a member of the group consisting of collagen receptors, laminin receptors, fibronectin receptors, chondroitin sulfate receptors, dermatan sulfate receptors, heparin sulfate receptors e, keratan sulfate receptors elastin receptors, and vitronectin receptors.

7. The collection of particles of claim 6 wherein the ligand is a member of the group consisting of a polypeptide, a growth factor, a growth factor fragment, and an antibody.

3. The collection of particles of claim 3 wherein the ligand is a member of the group consisting of a polypeptide, a carbohydrate, a glycosylated polypeptide, and an antibody.

5. The collection of particles of claim 5 wherein the ligand is a member of the group consisting of a polypeptide, a growth factor, a growth factor fragment, and an antibody.

9. A collection of particles comprising a bioactive component, a surfactant molecule having an HLB value of less than about 6.0 units, and a biocompatible polymer, wherein the collection of particles has an average diameter of less than about 200 nanometers as measured by atomic force microscopy of a plurality of the particles following drying of the particles, wherein the bioactive component is a member of the group consisting of anthracyclines, doxorubicin, vincristine, cyclophosphamide, topotecan, paclitaxel, modulators of apoptosis, and growth factors.

10. The collection of particles of claim 9, wherein the bioactive component is an antisense polynucleic acid.

11. The collection of particles of claim 9, wherein the bioactive component is a polynucleic acid.

12. The collection of particles of claim 9, wherein the bioactive component is a vector.

13. The collection of particles of claim 12, wherein the vector is a transposon.

14. A collection of particles comprising a bioactive component, a surfactant molecule having an HLB value of less than about 6.0 units, and a biocompatible polymer, wherein the particle has an average diameter of less than about 200 nanometers as measured by atomic force microscopy of a plurality of the particles following drying of the particles, and wherein the bioactive component is an antisense polynucleic acid effective to inhibit expression of CK2 polypeptides.

15. A method of delivering a bioactive component to a cell or tissue comprising

providing a collection of particles comprising a bioactive component, a surfactant having an HLB value of less than about 6.0 units, a biocompatible polymer, and a cell recognition component, wherein the particle has an average diameter of less than about 200 nanometers as measured by atomic force microscopy of a plurality of the particles following drying of the particles, wherein the cell recognition component has a binding affinity for a member of the group consisting of cell adhesion molecules, immunoglobulin superfamily, cell adhesion molecules, integrins, cadherins, selectins, growth factor receptors, collagen, laminin, fibronectin, chondroitin sulfate, dermatan sulfate, heparin sulfate, keratan sulfate, elastin, and vitronectin;

and

exposing the cell or tissue to the collection of particles.

16. The method of claim 15 wherein the cell is a member of the group consisting of glial cells, astrocytes, smooth muscle cells, myofibroblasts, vascular endothelial cells, leukaemic blasts, vascular endothelial cells in solid tumors, B-cell lymphoproliferative disease cells, acute myeloid leukemia cells, glial tumor cells, breast cancer cells, small-cell lung cancer cells, small cell ovarian cancer cells, colorectal cancer cells, and blood vessel medial cells.

17. A method of delivering an anti-cancer agent to cancer cells, the method comprising contacting the cancer cells with a collection of particles comprising the anticancer agents, a surfactant having an HLB value less than about 6.0 units, and a biocompatible polymer.

18. The method of claim 17 wherein the collection of particles further comprises a cell recognition component.

19. The method of claim 18 wherein the cell recognition component has a binding affinity for a cell recognition target, with the target being a member of the group consisting of cell adhesion molecules, immunoglobulin superfamily, cell adhesion molecules, integrins, cadherins, selectins, growth factor receptors, collagen receptors, laminin receptors, fibronectin receptors, chondroitin sulfate receptors, dermatan sulfate receptors, heparin sulfate receptors, keratan sulfate receptors, elastin receptors, and vitronectin receptors.

20. The method of claim 17 wherein the anticancer agent comprises a nucleic acid.

21. The method of claim 20 wherein the nucleic acid comprises an antisense sequence to a native human nucleic acid sequence.

22. The method of claim 21 wherein the antisense sequence is effective to inhibit expression of CK2.

23. The method of claim 17 wherein the anticancer agent comprises doxorubicin.

24. The method of claim 17 wherein the anticancer agent comprises an apoptotic agent.